U.S. News Room
September 06, 2022
Daiichi Sankyo Continues to Make Bold Strides in Oncology Across DXd ADC Portfolio at 2022 ESMO
Download
August 15, 2022
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Download
August 11, 2022
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Download